Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Larazotide - 9 Meters Biopharma

Next Previous
X
Search
Drug Profile

Larazotide - 9 Meters Biopharma

Alternative Names: AT-1001 - Alba Therapeutics; INN-202; INN-217; INN-289; Larazotide acetate; SPD 550

Latest Information Update: 20 Sep 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Maryland School of Medicine
  • Developer 9 Meters Biopharma; Alba Therapeutics; Alba Therapeutics Corporation; Beyond Celiac; Teva Pharmaceutical Industries; University of Virginia School of Medicine
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Hepatoprotectants; Irritable bowel syndrome therapies; Oligopeptides
  • Mechanism of Action Cell membrane permeability inhibitors; Myosin-light-chain kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Coeliac disease; Non-alcoholic steatohepatitis

Highest Development Phases

  • Discontinued Acute lung injury; Adult respiratory distress syndrome; Coeliac disease; Crohn's disease; Cryopyrin-associated periodic syndromes; Gastrointestinal disorders; Idiopathic pulmonary fibrosis; Irritable bowel syndrome; Liver failure; Non-alcoholic steatohepatitis; Type 1 diabetes mellitus

Most Recent Events

  • 20 Sep 2023 Discontinued - Phase-I for Irritable bowel syndrome in USA (PO)
  • 20 Sep 2023 Discontinued - Phase-II for Cryopyrin-associated periodic syndromes (In adolescents, In children, In infants, In adults) in USA (PO)
  • 20 Sep 2023 Discontinued - Preclinical for Acute lung injury in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top